Erlotinib in the treatment of advanced pancreatic cancer
Robin K Kelley, Andrew H KoUniversity of California, San Francisco, Comprehensive Cancer CenterAbstract: Single agent gemcitabine has been the mainstay of therapy for advanced pancreatic cancer over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in combination have...
Guardado en:
Autores principales: | Robin K Kelley, Andrew H Ko |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b03fe3d41223428eac15921ce749ba74 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
por: Nguyen KS, et al.
Publicado: (2012) -
Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan
por: Ko AH
Publicado: (2016) -
Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer.
por: Jasmine G Lee, et al.
Publicado: (2012) -
Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
por: Daniel A Monti, et al.
Publicado: (2012) -
Advancements in the endoscopic treatment of pancreatic fluid collections
por: Jing Li, et al.
Publicado: (2020)